Tag Hemophilia

Clinical Trials, News

Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the ISTH

Sanofi will present new data from its hemophilia portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), taking place June 22-26, 2024, in Bangkok, Thailand. Notable presentations on ALTUVIIIO [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein]…

June 21, 2024

New Treatments, News

FDA has approved BEQVEZ™ for the treatment of adults with moderate to severe hemophilia B

Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding…

April 26, 2024